Plain-English translation of NCT06970353 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new drug called to see if it can help people with advanced thyroid cancer that carries a specific genetic mutation (NRAS). The medication may be given alone or combined with another type of drug that helps the immune system fight cancer. The study will measure how well the treatment works and what side effects patients experience.
Many people with advanced thyroid cancer that doesn't respond to radioactive iodine treatment have limited options. This medication targets the specific genetic change (NRAS mutation) that drives some of these cancers, offering hope for a new treatment approach.
You likely qualify if…
You likely don't qualify if…
You will visit the study center for screening tests to confirm you qualify. Once enrolled, you will take the medication twice daily in 3-week treatment cycles, continuing until your cancer progresses, side effects become too severe, or you decide to stop. Every 9 weeks, you'll have imaging scans (CT or MRI) to check how your cancer is responding. You'll have a follow-up visit 30 days after your last dose, and then phone or clinic check-ins every 3 months to track your long-term health.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China